{"id":2808,"date":"2022-11-04T17:16:25","date_gmt":"2022-11-04T17:16:25","guid":{"rendered":"https:\/\/zenithpv.ca\/?p=572"},"modified":"2025-10-25T13:33:11","modified_gmt":"2025-10-25T17:33:11","slug":"les-processus-de-declaration-des-effets-indesirables-graves-des-medicaments-eiam-dans-les-hopitaux-canadiens","status":"publish","type":"post","link":"https:\/\/zenithpv.ca\/fr\/2022\/11\/04\/les-processus-de-declaration-des-effets-indesirables-graves-des-medicaments-eiam-dans-les-hopitaux-canadiens\/","title":{"rendered":"Les processus de d\u00e9claration des effets ind\u00e9sirables graves des m\u00e9dicaments (EIM) dans les h\u00f4pitaux canadiens"},"content":{"rendered":"<p>Lors de la conf\u00e9rence DIA 2022 \u00e0 Ottawa, Mme Marie-Claude Brutus L\u00f3pez, coordonnatrice du bureau r\u00e9gional de Canada Vigilance, a abord\u00e9 la d\u00e9claration obligatoire des incidents li\u00e9s aux instruments m\u00e9dicaux (IDM) et des effets ind\u00e9sirables graves des m\u00e9dicaments (EIM) par les h\u00f4pitaux. Vous trouverez ci-dessous un r\u00e9sum\u00e9 des principaux points \u00e0 retenir de vos partenaires PV chez Zenith PV.<\/p>\n<p><strong>D\u00e9claration obligatoire des h\u00f4pitaux (MRH) <\/strong><\/p>\n<p>D\u00e9cembre 2022 marque le troisi\u00e8me anniversaire de l&#039;entr\u00e9e en vigueur de la ligne directrice. Depuis sa mise en \u0153uvre en 2019, on a constat\u00e9 une l\u00e9g\u00e8re augmentation du nombre d&#039;IIM et d&#039;EI graves d\u00e9clar\u00e9s par les h\u00f4pitaux. Cependant, l&#039;industrie signale encore en moyenne 15 fois plus d&#039;EI et 8 fois plus d&#039;IIM que les h\u00f4pitaux. Il semble n\u00e9cessaire de relever les d\u00e9fis pour accro\u00eetre la conformit\u00e9 des h\u00f4pitaux. Sant\u00e9 Canada doit donc promouvoir davantage le cadre de d\u00e9claration, notamment en ce qui concerne la qualit\u00e9 des d\u00e9clarations, le mode de soumission et les d\u00e9lais, qui sont abord\u00e9s plus en d\u00e9tail ci-dessous.<\/p>\n<p><strong>Crit\u00e8res de d\u00e9claration <\/strong><\/p>\n<p><u>Effets ind\u00e9sirables graves d\u00e9finis comme :\u00a0 <\/u><\/p>\n<ul>\n<li>R\u00e9ponse nocive et involontaire \u00e0 un m\u00e9dicament, quelle que soit la dose, provoquant :<\/li>\n<li>Hospitalisation ou prolongation d&#039;une hospitalisation existante<\/li>\n<li>Malformation cong\u00e9nitale<\/li>\n<li>Invalidit\u00e9 ou incapacit\u00e9 persistante ou importante mena\u00e7ant la vie ou la mort<\/li>\n<li>\u00c9v\u00e9nement m\u00e9dical important (selon jugement m\u00e9dical)<\/li>\n<\/ul>\n<p><u>Incidents li\u00e9s aux dispositifs m\u00e9dicaux (IDM) : <\/u><\/p>\n<p><strong>En rapport avec : <\/strong><\/p>\n<ul>\n<li>La d\u00e9faillance d&#039;un dispositif m\u00e9dical<\/li>\n<li>D\u00e9t\u00e9rioration de son efficacit\u00e9, ou<\/li>\n<li>Insuffisance dans son \u00e9tiquetage ou ses instructions<\/li>\n<\/ul>\n<p><strong>Cela a conduit \u00e0 : <\/strong><\/p>\n<ul>\n<li>La mort ou<\/li>\n<li>D\u00e9t\u00e9rioration grave de la sant\u00e9 d\u2019un patient, d\u2019un utilisateur ou d\u2019une autre personne, ou<\/li>\n<li>Je pourrais le faire si cela devait se reproduire<\/li>\n<\/ul>\n<p><strong>M\u00e9thode de soumission <\/strong><\/p>\n<p>Plusieurs m\u00e9thodes de d\u00e9claration sont accept\u00e9es par le Programme Canada Vigilance, \u00e0 savoir :<\/p>\n<ol>\n<li>D\u00e9claration \u00e9lectronique<\/li>\n<li>Protocole de transfert de fichiers s\u00e9curis\u00e9 (sFTP)<\/li>\n<li>En ligne : via l&#039;application de d\u00e9claration en ligne de l&#039;h\u00f4pital ADR ou MDI<\/li>\n<li>Fax ou courrier<\/li>\n<\/ol>\n<p>T\u00e9l\u00e9chargez, imprimez, remplissez et t\u00e9l\u00e9copiez le formulaire PDF ADR \/ MDI au 1-866-678-6789<\/p>\n<p>OU<\/p>\n<p>Envoyez-le par la poste au Programme Canada Vigilance<\/p>\n<p><strong>Chronologies <\/strong><\/p>\n<p>La directive pr\u00e9voit la d\u00e9claration dans les <u>30 calendriers<\/u> jours de la premi\u00e8re documentation de la r\u00e9action ou de l&#039;incident au sein de l&#039;h\u00f4pital<\/p>\n<p><strong>Si votre h\u00f4pital a besoin d&#039;aide pour se conformer aux directives MRH de Sant\u00e9 Canada, Zenith PV peut vous accompagner \u00e0 chaque \u00e9tape. Contactez-nous d\u00e8s aujourd&#039;hui \u00e0 info@zenithpv.ca pour vous rapprocher de la conformit\u00e9 100%. <\/strong><\/p>\n<p>R\u00e9f\u00e9rence:<\/p>\n<p><a href=\"https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/medeffect-canada\/adverse-reaction-reporting\/mandatory-hospital-reporting\/drugs-devices\/guidance.html\">D\u00e9claration obligatoire des effets ind\u00e9sirables graves des m\u00e9dicaments et des incidents li\u00e9s aux instruments m\u00e9dicaux par les h\u00f4pitaux \u2013 Document d&#039;orientation \u2013 Canada.ca<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>L&#039;inspection GVP de Sant\u00e9 Canada est con\u00e7ue pour \u00e9valuer la conformit\u00e9 des titulaires d&#039;autorisations de mise sur le march\u00e9 \u00e9trangers et locaux aux lignes directrices GVP, afin de garantir qu&#039;un syst\u00e8me ad\u00e9quat est en place pour surveiller l&#039;utilisation s\u00fbre et efficace des m\u00e9dicaments.1 \u00c0 ce titre, l&#039;\u00e9valuation de la conformit\u00e9 est essentielle \u00e0 la continuit\u00e9 des soins et \u00e0 l&#039;am\u00e9lioration des patients.<\/p>","protected":false},"author":1,"featured_media":2817,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[18],"tags":[],"class_list":["post-2808","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-articles"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v26.2 (Yoast SEO v26.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>The processes for reporting Serious Adverse Drug Reactions (ADRs) at Canadian Hospitals - ZenithPV<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/zenithpv.ca\/fr\/2022\/11\/04\/les-processus-de-declaration-des-effets-indesirables-graves-des-medicaments-eiam-dans-les-hopitaux-canadiens\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The processes for reporting Serious Adverse Drug Reactions (ADRs) at Canadian Hospitals\" \/>\n<meta property=\"og:description\" content=\"Health Canada GVP inspection is designed to assess compliance of foreign and local MAHs to the GVP guidelines, to ensure an adequate system is in place for monitoring the safe and effective use of medicinal products.1 As such, compliant rating is critical to the continuity of care and betterment of patients.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/zenithpv.ca\/fr\/2022\/11\/04\/les-processus-de-declaration-des-effets-indesirables-graves-des-medicaments-eiam-dans-les-hopitaux-canadiens\/\" \/>\n<meta property=\"og:site_name\" content=\"ZenithPV\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-04T17:16:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-25T17:33:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/zenithpv.ca\/wp-content\/uploads\/2022\/11\/healthcare-hipaa-compliant.png\" \/>\n\t<meta property=\"og:image:width\" content=\"788\" \/>\n\t<meta property=\"og:image:height\" content=\"443\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Lloyd\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Lloyd\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimation du temps de lecture\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/zenithpv.ca\/2022\/11\/04\/the-processes-for-reporting-serious-adverse-drug-reactions-adrs-at-canadian-hospitals\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/zenithpv.ca\/2022\/11\/04\/the-processes-for-reporting-serious-adverse-drug-reactions-adrs-at-canadian-hospitals\/\"},\"author\":{\"name\":\"Lloyd\",\"@id\":\"https:\/\/zenithpv.ca\/#\/schema\/person\/c6ffd5788a77ffd2fbc6de6113f041a3\"},\"headline\":\"The processes for reporting Serious Adverse Drug Reactions (ADRs) at Canadian Hospitals\",\"datePublished\":\"2022-11-04T17:16:25+00:00\",\"dateModified\":\"2025-10-25T17:33:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/zenithpv.ca\/2022\/11\/04\/the-processes-for-reporting-serious-adverse-drug-reactions-adrs-at-canadian-hospitals\/\"},\"wordCount\":379,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/zenithpv.ca\/#organization\"},\"image\":{\"@id\":\"https:\/\/zenithpv.ca\/2022\/11\/04\/the-processes-for-reporting-serious-adverse-drug-reactions-adrs-at-canadian-hospitals\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/zenithpv.ca\/wp-content\/uploads\/2022\/11\/healthcare-hipaa-compliant.png\",\"articleSection\":[\"Articles\"],\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/zenithpv.ca\/2022\/11\/04\/the-processes-for-reporting-serious-adverse-drug-reactions-adrs-at-canadian-hospitals\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/zenithpv.ca\/2022\/11\/04\/the-processes-for-reporting-serious-adverse-drug-reactions-adrs-at-canadian-hospitals\/\",\"url\":\"https:\/\/zenithpv.ca\/2022\/11\/04\/the-processes-for-reporting-serious-adverse-drug-reactions-adrs-at-canadian-hospitals\/\",\"name\":\"The processes for reporting Serious Adverse Drug Reactions (ADRs) at Canadian Hospitals - ZenithPV\",\"isPartOf\":{\"@id\":\"https:\/\/zenithpv.ca\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/zenithpv.ca\/2022\/11\/04\/the-processes-for-reporting-serious-adverse-drug-reactions-adrs-at-canadian-hospitals\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/zenithpv.ca\/2022\/11\/04\/the-processes-for-reporting-serious-adverse-drug-reactions-adrs-at-canadian-hospitals\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/zenithpv.ca\/wp-content\/uploads\/2022\/11\/healthcare-hipaa-compliant.png\",\"datePublished\":\"2022-11-04T17:16:25+00:00\",\"dateModified\":\"2025-10-25T17:33:11+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/zenithpv.ca\/2022\/11\/04\/the-processes-for-reporting-serious-adverse-drug-reactions-adrs-at-canadian-hospitals\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/zenithpv.ca\/2022\/11\/04\/the-processes-for-reporting-serious-adverse-drug-reactions-adrs-at-canadian-hospitals\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\/\/zenithpv.ca\/2022\/11\/04\/the-processes-for-reporting-serious-adverse-drug-reactions-adrs-at-canadian-hospitals\/#primaryimage\",\"url\":\"https:\/\/zenithpv.ca\/wp-content\/uploads\/2022\/11\/healthcare-hipaa-compliant.png\",\"contentUrl\":\"https:\/\/zenithpv.ca\/wp-content\/uploads\/2022\/11\/healthcare-hipaa-compliant.png\",\"width\":788,\"height\":443},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/zenithpv.ca\/2022\/11\/04\/the-processes-for-reporting-serious-adverse-drug-reactions-adrs-at-canadian-hospitals\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/zenithpv.ca\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The processes for reporting Serious Adverse Drug Reactions (ADRs) at Canadian Hospitals\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/zenithpv.ca\/#website\",\"url\":\"https:\/\/zenithpv.ca\/\",\"name\":\"ZenithPV\",\"description\":\"Specialists In Pharmacovigilance, Canada\",\"publisher\":{\"@id\":\"https:\/\/zenithpv.ca\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/zenithpv.ca\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/zenithpv.ca\/#organization\",\"name\":\"Zenith PV Solutions Inc.\",\"url\":\"https:\/\/zenithpv.ca\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\/\/zenithpv.ca\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/zenithpv.ca\/wp-content\/uploads\/2022\/07\/ZenithLogo.png\",\"contentUrl\":\"https:\/\/zenithpv.ca\/wp-content\/uploads\/2022\/07\/ZenithLogo.png\",\"width\":625,\"height\":125,\"caption\":\"Zenith PV Solutions Inc.\"},\"image\":{\"@id\":\"https:\/\/zenithpv.ca\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/ca.linkedin.com\/company\/zenithpv\",\"https:\/\/www.youtube.com\/channel\/UCvQfRUpb7WdvF3I8PX9pdXA\"],\"description\":\"Zenith PV pride ourself on deep industry knowledge and a network of experts in pharmacovigilance, regulatory affairs, and quality assurance.\",\"email\":\"info@zenithpv.ca\",\"telephone\":\"(416) 807-5441\",\"numberOfEmployees\":{\"@type\":\"QuantitativeValue\",\"minValue\":\"11\",\"maxValue\":\"50\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/zenithpv.ca\/#\/schema\/person\/c6ffd5788a77ffd2fbc6de6113f041a3\",\"name\":\"Lloyd\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\/\/zenithpv.ca\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/0d2967ec5152a2bf43a21bd5ceb8e4e2a40dd45c5efe58f731a0cebbdd8bcef9?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/0d2967ec5152a2bf43a21bd5ceb8e4e2a40dd45c5efe58f731a0cebbdd8bcef9?s=96&d=mm&r=g\",\"caption\":\"Lloyd\"},\"sameAs\":[\"https:\/\/zenithpv.ca\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Processus de d\u00e9claration des effets ind\u00e9sirables graves des m\u00e9dicaments (EIM) dans les h\u00f4pitaux canadiens - ZenithPV","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/zenithpv.ca\/fr\/2022\/11\/04\/les-processus-de-declaration-des-effets-indesirables-graves-des-medicaments-eiam-dans-les-hopitaux-canadiens\/","og_locale":"fr_CA","og_type":"article","og_title":"The processes for reporting Serious Adverse Drug Reactions (ADRs) at Canadian Hospitals","og_description":"Health Canada GVP inspection is designed to assess compliance of foreign and local MAHs to the GVP guidelines, to ensure an adequate system is in place for monitoring the safe and effective use of medicinal products.1 As such, compliant rating is critical to the continuity of care and betterment of patients.","og_url":"https:\/\/zenithpv.ca\/fr\/2022\/11\/04\/les-processus-de-declaration-des-effets-indesirables-graves-des-medicaments-eiam-dans-les-hopitaux-canadiens\/","og_site_name":"ZenithPV","article_published_time":"2022-11-04T17:16:25+00:00","article_modified_time":"2025-10-25T17:33:11+00:00","og_image":[{"width":788,"height":443,"url":"https:\/\/zenithpv.ca\/wp-content\/uploads\/2022\/11\/healthcare-hipaa-compliant.png","type":"image\/png"}],"author":"Lloyd","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Lloyd","Estimation du temps de lecture":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/zenithpv.ca\/2022\/11\/04\/the-processes-for-reporting-serious-adverse-drug-reactions-adrs-at-canadian-hospitals\/#article","isPartOf":{"@id":"https:\/\/zenithpv.ca\/2022\/11\/04\/the-processes-for-reporting-serious-adverse-drug-reactions-adrs-at-canadian-hospitals\/"},"author":{"name":"Lloyd","@id":"https:\/\/zenithpv.ca\/#\/schema\/person\/c6ffd5788a77ffd2fbc6de6113f041a3"},"headline":"The processes for reporting Serious Adverse Drug Reactions (ADRs) at Canadian Hospitals","datePublished":"2022-11-04T17:16:25+00:00","dateModified":"2025-10-25T17:33:11+00:00","mainEntityOfPage":{"@id":"https:\/\/zenithpv.ca\/2022\/11\/04\/the-processes-for-reporting-serious-adverse-drug-reactions-adrs-at-canadian-hospitals\/"},"wordCount":379,"commentCount":0,"publisher":{"@id":"https:\/\/zenithpv.ca\/#organization"},"image":{"@id":"https:\/\/zenithpv.ca\/2022\/11\/04\/the-processes-for-reporting-serious-adverse-drug-reactions-adrs-at-canadian-hospitals\/#primaryimage"},"thumbnailUrl":"https:\/\/zenithpv.ca\/wp-content\/uploads\/2022\/11\/healthcare-hipaa-compliant.png","articleSection":["Articles"],"inLanguage":"fr-CA","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/zenithpv.ca\/2022\/11\/04\/the-processes-for-reporting-serious-adverse-drug-reactions-adrs-at-canadian-hospitals\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/zenithpv.ca\/2022\/11\/04\/the-processes-for-reporting-serious-adverse-drug-reactions-adrs-at-canadian-hospitals\/","url":"https:\/\/zenithpv.ca\/2022\/11\/04\/the-processes-for-reporting-serious-adverse-drug-reactions-adrs-at-canadian-hospitals\/","name":"Processus de d\u00e9claration des effets ind\u00e9sirables graves des m\u00e9dicaments (EIM) dans les h\u00f4pitaux canadiens - ZenithPV","isPartOf":{"@id":"https:\/\/zenithpv.ca\/#website"},"primaryImageOfPage":{"@id":"https:\/\/zenithpv.ca\/2022\/11\/04\/the-processes-for-reporting-serious-adverse-drug-reactions-adrs-at-canadian-hospitals\/#primaryimage"},"image":{"@id":"https:\/\/zenithpv.ca\/2022\/11\/04\/the-processes-for-reporting-serious-adverse-drug-reactions-adrs-at-canadian-hospitals\/#primaryimage"},"thumbnailUrl":"https:\/\/zenithpv.ca\/wp-content\/uploads\/2022\/11\/healthcare-hipaa-compliant.png","datePublished":"2022-11-04T17:16:25+00:00","dateModified":"2025-10-25T17:33:11+00:00","breadcrumb":{"@id":"https:\/\/zenithpv.ca\/2022\/11\/04\/the-processes-for-reporting-serious-adverse-drug-reactions-adrs-at-canadian-hospitals\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/zenithpv.ca\/2022\/11\/04\/the-processes-for-reporting-serious-adverse-drug-reactions-adrs-at-canadian-hospitals\/"]}]},{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/zenithpv.ca\/2022\/11\/04\/the-processes-for-reporting-serious-adverse-drug-reactions-adrs-at-canadian-hospitals\/#primaryimage","url":"https:\/\/zenithpv.ca\/wp-content\/uploads\/2022\/11\/healthcare-hipaa-compliant.png","contentUrl":"https:\/\/zenithpv.ca\/wp-content\/uploads\/2022\/11\/healthcare-hipaa-compliant.png","width":788,"height":443},{"@type":"BreadcrumbList","@id":"https:\/\/zenithpv.ca\/2022\/11\/04\/the-processes-for-reporting-serious-adverse-drug-reactions-adrs-at-canadian-hospitals\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/zenithpv.ca\/"},{"@type":"ListItem","position":2,"name":"The processes for reporting Serious Adverse Drug Reactions (ADRs) at Canadian Hospitals"}]},{"@type":"WebSite","@id":"https:\/\/zenithpv.ca\/#website","url":"https:\/\/zenithpv.ca\/","name":"ZenithPV","description":"Sp\u00e9cialistes en pharmacovigilance, Canada","publisher":{"@id":"https:\/\/zenithpv.ca\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/zenithpv.ca\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/zenithpv.ca\/#organization","name":"Zenith PV Solutions Inc.","url":"https:\/\/zenithpv.ca\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/zenithpv.ca\/#\/schema\/logo\/image\/","url":"https:\/\/zenithpv.ca\/wp-content\/uploads\/2022\/07\/ZenithLogo.png","contentUrl":"https:\/\/zenithpv.ca\/wp-content\/uploads\/2022\/07\/ZenithLogo.png","width":625,"height":125,"caption":"Zenith PV Solutions Inc."},"image":{"@id":"https:\/\/zenithpv.ca\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/ca.linkedin.com\/company\/zenithpv","https:\/\/www.youtube.com\/channel\/UCvQfRUpb7WdvF3I8PX9pdXA"],"description":"Zenith PV est fi\u00e8re de sa connaissance approfondie du secteur et de son r\u00e9seau d&#039;experts en pharmacovigilance, affaires r\u00e9glementaires et assurance qualit\u00e9.","email":"info@zenithpv.ca","telephone":"(416) 807-5441","numberOfEmployees":{"@type":"QuantitativeValue","minValue":"11","maxValue":"50"}},{"@type":"Person","@id":"https:\/\/zenithpv.ca\/#\/schema\/person\/c6ffd5788a77ffd2fbc6de6113f041a3","name":"Lloyd","image":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/zenithpv.ca\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/0d2967ec5152a2bf43a21bd5ceb8e4e2a40dd45c5efe58f731a0cebbdd8bcef9?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/0d2967ec5152a2bf43a21bd5ceb8e4e2a40dd45c5efe58f731a0cebbdd8bcef9?s=96&d=mm&r=g","caption":"Lloyd"},"sameAs":["https:\/\/zenithpv.ca"]}]}},"_links":{"self":[{"href":"https:\/\/zenithpv.ca\/fr\/wp-json\/wp\/v2\/posts\/2808","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/zenithpv.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/zenithpv.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/zenithpv.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/zenithpv.ca\/fr\/wp-json\/wp\/v2\/comments?post=2808"}],"version-history":[{"count":0,"href":"https:\/\/zenithpv.ca\/fr\/wp-json\/wp\/v2\/posts\/2808\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/zenithpv.ca\/fr\/wp-json\/wp\/v2\/media\/2817"}],"wp:attachment":[{"href":"https:\/\/zenithpv.ca\/fr\/wp-json\/wp\/v2\/media?parent=2808"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/zenithpv.ca\/fr\/wp-json\/wp\/v2\/categories?post=2808"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/zenithpv.ca\/fr\/wp-json\/wp\/v2\/tags?post=2808"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}